長實集團(01113.HK)要約回購3.8億股股份已註銷
格隆匯6月4日丨長實集團(01113.HK)宣佈,公司根據股份回購要約回購的3.8億股股份已於2021年6月4日(星期五)註銷(“要約完成”)。因此,緊隨要約完成後,(i)已發行股份總數由4,026,733,833股股份削減380,000,000股股份至3,646,733,833股股份及(ii)控股股東集團持有的權益總額由佔全部已發行股份約41.29%增加至約45.60%。
香港股份登記處將於2021年6月7日(星期一)或之前以普通郵遞方式寄發根據股份回購要約應付予各接納股東的款項總額。涉及未獲接納股份餘額的所有權文件或補發股票亦將於2021年6月7日(星期一)或之前退回或寄發予各接納股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.